Scientific publications

A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, INF alpha, and IL-1 beta

Sep 2, 2022 | Magazine: Cancer Discovery

Irene Olivera # 1 2, Rebeca Sanz-Pamplona # 3, Elixabet Bolaños 1 2, Inmaculada Rodriguez 1 2, Iñaki Etxeberria 1 2, Assunta Cirella 1 2, Josune Egea 1 2, Saray Garasa 1 4, Itziar Migueliz 1 2, Iñaki Eguren-Santamaria 1 2, Miguel F Sanmamed 1 2 4, Javier Glez-Vaz 1 2, Arantza Azpilikueta 1 2, Maite Alvarez 1 2 4, María C Ochoa 1 4, Beatrice Malacrida 5, David Propper 5, Carlos E de Andrea 4 6, Pedro Berraondo 1 2 4, Frances R Balkwill 5, Álvaro Teijeira # 1 2 4, Ignacio Melero # 1 2 4 7


Interleukin-8 (CXCL8) produced in the tumor microenvironment correlates with poor response to checkpoint inhibitors and is known to chemoattract and activate immunosuppressive myeloid leukocytes. In human cancer, IL8 mRNA levels correlate with IL1B and TNF transcripts.

Both cytokines induced IL-8 functional expression from a broad variety of human cancer cell lines, primary colon carcinoma organoids, and fresh human tumor explants. Although IL8 is absent from the mouse genome, a similar murine axis in which TNFα and IL-1β upregulate CXCL1 and CXCL2 in tumor cells was revealed.

Furthermore, intratumoral injection of TNFα and IL-1β induced IL-8 release from human malignant cells xenografted in immunodeficient mice. In all these cases, the clinically used TNFα blockers infliximab and etanercept or the IL-1β inhibitor anakinra was able to interfere with this pathogenic cytokine loop. Finally, in paired plasma samples of patients with cancer undergoing TNFα blockade with infliximab in a clinical trial, reductions of circulating IL-8 were substantiated.

Significance: IL-8 attracts immunosuppressive protumor myeloid cells to the tumor microenvironment, and IL-8 levels correlate with poor response to checkpoint inhibitors. TNFα and IL-1β are identified as major inducers of IL-8 expression on malignant cells across cancer types and models in a manner that is druggable with clinically available neutralizing agents. This article is highlighted in the In This Issue feature, p. 2007.

CITA DEL ARTÍCULO  Cancer Discov. 2022 Sep 2;12(9):2140-2157. doi: 10.1158/2159-8290.CD-21-1115.